MQS Management’s Catalyst Pharmaceutical CPRX Stock Holding History

MQS Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,156	Closed	-$200K	–	455
2025 Q3	$200K	Buy	+10,156	New	+$209K	0.12%	377

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MQS Management's CPRX Position: Q4 2025 in Review

MQS Management sold out of Catalyst Pharmaceutical (CPRX) in Q4 2025, closing a stake of 10,156 shares — an estimated $200K sold.

MQS Management first reported a position in CPRX in Q3 2025 and held it in 1 quarter. The position peaked at $200K in Q3 2025. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

MQS Management reported no remaining Catalyst Pharmaceutical position as of Q4 2025 after selling out during the quarter.
MQS Management sold 10,156 Catalyst Pharmaceutical shares in Q4 2025, an estimated $200K.
MQS Management first reported a position in Catalyst Pharmaceutical in Q3 2025 and held it in 1 quarter.
MQS Management's Catalyst Pharmaceutical position peaked at $200K in Q3 2025.
373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on MQS Management's 13F filing for Q4 2025, filed 9 Feb 2026.